Sales Rep's Free Speech Challenge Of Off-Label Regs Boosted By Sorrell Ruling
Executive Summary
The Supreme Court's ruling that Vermont's prescriber data mining law violates the First Amendment could help a pharma sales representative to overturn his conviction for promoting a drug for off-label uses.
You may also be interested in...
Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling
In a watershed decision, a federal appeals court declares that manufacturers cannot be prosecuted under the FD&C Act’s misbranding provisions solely for speech promoting off-label use of a drug. Industry attorneys predict the decision, if it stands, will change the government’s approach to pursuing such cases.
Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling
In a watershed decision, a federal appeals court declares that manufacturers cannot be prosecuted under the FD&C Act’s misbranding provisions solely for speech promoting off-label use of a drug. Industry attorneys predict the decision, if it stands, will change the government’s approach to pursuing such cases.
Ruling Against Cigarette Warnings Could Impact Other FDA Labeling
A judge’s opinion that requiring graphic images on cigarette packages unconstitutionally compels speech could affect FDA’s qualifications for supplement health claims and its off-label rules. FDA “carries the burden of proving” the required speech is truthful and accurate, says attorney Jonathan Emord.